The industry's evolving, so are we

Article

Sometimes I sit back and think about how this magazine has evolved over the years and, on a more regular basis, I think about where we can go from here.

Sometimes I sit back and think about how this magazine has evolved over the years and, on a more regular basis, I think about where we can go from here.

I often call upon the advice of our esteemed Editorial Advisory Board members to guide the editorial direction of this magazine; however, the thoughts of our readers are also of paramount importance. As such, I am incredibly grateful to you for your involvement in readership surveys and for the comments I have received from you by E-mail and at congresses. This really has helped us to serve you better.

As the ophthalmology industry evolves, so too do your needs and as such, we want to make sure that we are providing you with exactly what you want, when you want it.

This is just one example of some of the changes that we are making. Please do keep your suggestions coming because we are listening and every one of your opinions and ideas is taken on board. Ultimately, Ophthalmology Times Europe is your information source so make sure it's perfect for you.

Best wishes,

Fedra Pavlou
Editor
fpavlou@advanstar.com

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.